| 摘要 |
For prophylaxis or treatment of coagulation disorders or cancer an extrinsic pathway inhibitor (EPI) is administered together with heparin or other mucopolysaccharide to the patient. Thereby an increase in coagulant activity is obtained as well as an increase of half-life of injected EPI in plasma. |
